PL2785373T3 - Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania - Google Patents

Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania

Info

Publication number
PL2785373T3
PL2785373T3 PL12801680T PL12801680T PL2785373T3 PL 2785373 T3 PL2785373 T3 PL 2785373T3 PL 12801680 T PL12801680 T PL 12801680T PL 12801680 T PL12801680 T PL 12801680T PL 2785373 T3 PL2785373 T3 PL 2785373T3
Authority
PL
Poland
Prior art keywords
vectors expressing
recombinant hvt
expressing antigens
avian pathogens
hvt vectors
Prior art date
Application number
PL12801680T
Other languages
English (en)
Polish (pl)
Inventor
Michel Bublot
Teshome Mebatsion
Joyce Pritchard
Perry LINZ
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2785373(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Publication of PL2785373T3 publication Critical patent/PL2785373T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL12801680T 2011-11-30 2012-11-29 Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania PL2785373T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US201261694957P 2012-08-30 2012-08-30
PCT/US2012/067135 WO2013082327A1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
EP12801680.5A EP2785373B1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Publications (1)

Publication Number Publication Date
PL2785373T3 true PL2785373T3 (pl) 2020-06-01

Family

ID=47358292

Family Applications (3)

Application Number Title Priority Date Filing Date
PL12801680T PL2785373T3 (pl) 2011-11-30 2012-11-29 Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania
PL12805843.5T PL2785374T5 (pl) 2011-11-30 2012-11-29 Rekombinowane wektory Gallid herpesvirus3 (MDV serotypu 2) wyrażające antygeny patogenów ptasich i ich zastosowanie
PL17179863T PL3251691T3 (pl) 2011-11-30 2012-11-29 Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12805843.5T PL2785374T5 (pl) 2011-11-30 2012-11-29 Rekombinowane wektory Gallid herpesvirus3 (MDV serotypu 2) wyrażające antygeny patogenów ptasich i ich zastosowanie
PL17179863T PL3251691T3 (pl) 2011-11-30 2012-11-29 Rekombinowane wektory HVT wyrażające antygeny ptasich patogenów i ich zastosowania

Country Status (28)

Country Link
EP (7) EP3578199A1 (ru)
JP (1) JP6149301B2 (ru)
KR (1) KR102013135B1 (ru)
CN (3) CN104159604B (ru)
AR (2) AR090401A1 (ru)
BR (1) BR112014013276B1 (ru)
CA (1) CA2857025C (ru)
CO (1) CO7061033A2 (ru)
CY (3) CY1121528T1 (ru)
DK (3) DK2785374T3 (ru)
ES (3) ES2785045T3 (ru)
HK (4) HK1197175A1 (ru)
HR (3) HRP20190525T8 (ru)
HU (3) HUE042471T2 (ru)
IN (1) IN2014CN04833A (ru)
LT (3) LT2785373T (ru)
ME (1) ME03433B (ru)
MX (2) MX361893B (ru)
PE (1) PE20141482A1 (ru)
PH (2) PH12014501174B1 (ru)
PL (3) PL2785373T3 (ru)
PT (3) PT2785374T (ru)
RS (3) RS59893B1 (ru)
RU (1) RU2620936C2 (ru)
SI (3) SI3251691T1 (ru)
UA (1) UA118651C2 (ru)
WO (2) WO2013082317A2 (ru)
ZA (1) ZA201403804B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103890183A (zh) 2011-10-21 2014-06-25 英特维特国际股份有限公司 编码传染性喉气管炎病毒和新城疫病毒抗原的重组非致病性马立克氏病病毒构建体
PT2785374T (pt) 2011-11-30 2019-05-09 Merial Ltd Vectores recombinantes do herpesvírus 3 dos galídeos (mdv serotipo 2) expressando antigénios de agentes patogénicos aviários e suas utilizações
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
WO2017027324A1 (en) * 2015-08-10 2017-02-16 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
ES2935643T3 (es) 2016-06-17 2023-03-08 Intervet Int Bv Construcciones de virus de la enfermedad de Marek no patógeno recombinante que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la bursitis infecciosa
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
EP3554536B1 (en) 2016-12-14 2022-10-26 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
CN106701693A (zh) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
CN106929483B (zh) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
EP3694987A1 (en) * 2017-10-12 2020-08-19 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens
JP7448475B2 (ja) 2017-12-20 2024-03-12 インターベット インターナショナル ベー． フェー． 細胞関連アルファヘルペスウイルスワクチン用の改善された希釈液
CN108543067A (zh) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
EP3743084A4 (en) * 2018-01-24 2021-12-08 Virogin Biotech Canada Ltd RECOMBINANT ANTIVIRAL VACCINES
CN109468315B (zh) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 水稻耐淹基因Sub1共显性分子标记及应用
KR20210108971A (ko) 2018-12-21 2021-09-03 세바 상뜨 아니말르 다수의 외래 유전자를 함유하는 재조합 조류 헤르페스 바이러스
US11464849B2 (en) * 2019-09-11 2022-10-11 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN110872578B (zh) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease
CN116472057A (zh) 2020-06-17 2023-07-21 勃林格殷格翰动物保健有限公司 表达流感血凝素的重组hvt载体和免疫原性组合物，以及其生产和用途
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
EP4228683A2 (en) 2020-10-15 2023-08-23 Ceva Santé Animale Recombinant hvt and uses thereof
CN114317827B (zh) * 2022-01-07 2023-03-24 河南省农业科学院 一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2719056B1 (fr) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
ES2360298T3 (es) * 1994-08-09 2011-06-02 Schering-Plough Ltd. Herpesvirus recombinantes de pavos y sus usos.
RU2059414C1 (ru) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) * 1996-06-21 1998-01-13 Univ Michigan State マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6632664B1 (en) * 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko) * 2000-04-11 2002-10-05 대한민국 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) * 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2419132B1 (en) * 2009-04-15 2014-06-25 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
PT2785374T (pt) 2011-11-30 2019-05-09 Merial Ltd Vectores recombinantes do herpesvírus 3 dos galídeos (mdv serotipo 2) expressando antigénios de agentes patogénicos aviários e suas utilizações

Also Published As

Publication number Publication date
HRP20192215T1 (hr) 2020-02-21
HK1200018A1 (en) 2015-07-31
AR089039A1 (es) 2014-07-23
PH12014501174A1 (en) 2014-09-08
BR112014013276A2 (pt) 2018-05-15
EP2785374B1 (en) 2019-01-09
CN104159604B (zh) 2016-08-24
LT2785373T (lt) 2020-02-10
KR20140097515A (ko) 2014-08-06
BR112014013276B1 (pt) 2021-07-27
HUE047909T2 (hu) 2020-05-28
EP2785373A1 (en) 2014-10-08
MX361893B (es) 2018-12-18
HRP20190525T4 (hr) 2023-01-20
RU2014126375A (ru) 2016-01-27
PH12014501174B1 (en) 2014-09-08
PL3251691T3 (pl) 2020-06-01
DK2785373T3 (da) 2020-02-03
ES2719409T5 (es) 2022-12-07
WO2013082317A8 (en) 2014-07-10
CO7061033A2 (es) 2014-09-19
SI2785373T1 (sl) 2020-02-28
EP2785373B1 (en) 2019-11-20
CN104159604A (zh) 2014-11-19
EP3572092A1 (en) 2019-11-27
KR102013135B1 (ko) 2019-08-22
HK1248566A1 (zh) 2018-10-19
HUE042471T2 (hu) 2019-07-29
ES2719409T3 (es) 2019-07-10
RS59893B1 (sr) 2020-03-31
HRP20190525T8 (hr) 2023-01-20
ME03433B (me) 2020-01-20
RS59892B1 (sr) 2020-03-31
CN104159605B (zh) 2019-04-19
WO2013082327A1 (en) 2013-06-06
ES2775218T3 (es) 2020-07-24
DK3251691T3 (da) 2020-02-10
RU2620936C2 (ru) 2017-05-30
ZA201403804B (en) 2015-04-29
AR090401A1 (es) 2014-11-12
PT2785374T (pt) 2019-05-09
CN105920598A (zh) 2016-09-07
SI2785374T1 (sl) 2019-04-30
EP3251691A1 (en) 2017-12-06
LT2785374T (lt) 2019-04-25
PT3251691T (pt) 2020-01-28
WO2013082317A2 (en) 2013-06-06
CY1121528T1 (el) 2020-05-29
CY1124618T1 (el) 2022-03-24
MX365984B (es) 2019-06-21
DK2785374T3 (en) 2019-04-08
EP3251691B1 (en) 2019-11-20
PH12015502790B1 (en) 2017-07-10
JP2015500806A (ja) 2015-01-08
EP2785374B2 (en) 2022-08-17
WO2013082317A3 (en) 2013-08-15
CY1122872T1 (el) 2021-05-05
ES2785045T3 (es) 2020-10-05
HK1197175A1 (en) 2015-01-09
HK1247832A1 (zh) 2018-10-05
HRP20192241T1 (hr) 2020-03-06
PL2785374T5 (pl) 2023-01-09
SI3251691T1 (sl) 2020-02-28
PT2785373T (pt) 2020-01-27
EP3263130A1 (en) 2018-01-03
CA2857025C (en) 2021-08-03
EP2785374A2 (en) 2014-10-08
HRP20190525T1 (hr) 2019-05-03
PH12015502790A1 (en) 2017-07-10
JP6149301B2 (ja) 2017-06-21
CA2857025A1 (en) 2013-06-06
IN2014CN04833A (ru) 2015-09-18
CN104159605A (zh) 2014-11-19
UA118651C2 (uk) 2019-02-25
EP4112073A1 (en) 2023-01-04
MX2014006360A (es) 2015-03-05
WO2013082327A8 (en) 2014-07-03
MX2014006361A (es) 2015-03-05
PE20141482A1 (es) 2014-11-08
HUE047724T2 (hu) 2020-05-28
RS58610B1 (sr) 2019-05-31
LT3251691T (lt) 2020-02-10
EP3578199A1 (en) 2019-12-11
PL2785374T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
HK1197175A1 (en) Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof hvt
IL260045B (en) Polypeptide structures and their uses
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
IL279676A (en) Recombinant proteins and therapeutic uses
HK1197187A1 (en) Anti-lrp5 antibodies and methods of use lrp5
EP2598636A4 (en) VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS
EP2553105A4 (en) COMPOSITIONS AND METHOD FOR PRODUCING RECOMBINANT VIRUS VECTORS
HK1210079A1 (en) Biglycan variant polypeptides and methods of use
EP2739306A4 (en) OPTIMIZED ANTIGENS OF PNEUMOCYSTOSIS AND THEIR USE